Emicizumab and Acquired Hemophilia A Secondary to Multiple Myeloma
Emicizumab, in conjunction with targeted myeloma treatment, represents a promising strategy to improve outcomes for AHA patients with MM. This approach is particularly advantageous for older patients with multiple comorbidities, who face elevated risks of thrombotic, bleeding, and infectious complications.
Authors
- Cedric R.J.R. Hermans (ORCID: https://orcid.org/0000-0001-5429-8437)
- Florence Cuschera
- Marie-Christiane Vekemans
Institutions
- Cliniques Universitaires Saint-Luc (BE)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1159/000545442
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00